Valentina Molteni

Valentina Molteni

Auto-generated profile, based on publicly available information

Valentina Molteni

The Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2014 in Chemical Reviews
Verified
Journal Article
Open access
ANAdvait S. Nagle
Advait S. Nagle
SKShilpi Khare
Shilpi Khare
AKArun Babu Kumar
Arun Babu Kumar
FSFrantisek Supek
Frantisek Supek
ABAndriy Buchynskyy
Andriy Buchynskyy
VMValentina Molteni
Valentina Molteni

15 July 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ANAdvait Nagle
Advait Nagle
ABAgnes Biggart
Agnes Biggart
CBCeline Be
Celine Be
HSHonnappa Srinivas
Honnappa Srinivas
AHAndreas Hein
Andreas Hein
VMValentina Molteni
Valentina Molteni
Visceral leishmaniasis is responsible for up to 30,000 deaths every year. Current treatments have shortcomings that include toxicity and variable efficacy across endemic regions. Previously, we reported the discovery of GNF6702, a selective inhibitor of the kinetoplastid proteasome, which cleared parasites in murine models of leishmaniasis, Chagas disease and human African trypamomiasis. Here, we describe the discovery and characterization of LXE408, a structurally related kinetoplastid-selective proteasome inhibitor currently in Phase 1 human clinical trials. Furthermore, we present high-resolution cryo-EM structures of the Leishmania tarentolae proteasome in complex with LXE408, which provides a compelling explanation for the non-competitive mode of binding of this novel class of inhibitors of the kinetoplastid proteasome.

15 January 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
DCDonatella Chianelli
Donatella Chianelli
PRPaul V. Rucker
Paul V. Rucker
JRJason Roland
Jason Roland
DTDavid C. Tully
David C. Tully
JNJohn Nelson
John Nelson
VMValentina Molteni
Valentina Molteni
Farnesoid X receptor (FXR) agonists are emerging as important potential therapeutics for the treatment of nonalcoholic steatohepatitis (NASH) patients as they exert positive effects on multiple aspects of the disease. FXR agonists reduce lipid accumulation in the liver, hepatocellular inflammation, hepatic injury and fibrosis. While there are currently no approved therapies for NASH, the bile acid-derived FXR agonist obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid) has shown promise in clinical studies. Previously, we described the discovery of tropifexor (LJN452), the most potent non-bile acid FXR agonist currently in clinical investigation. Here, we report the discovery of a novel chemical series of non-bile acid FXR agonists based on a tricyclic dihydrochromenopyrazole core from which emerged nidufexor (LMB763), a compound with partial FXR agonistic activity in vitro and FXR-dependent gene modulation in vivo. Nidufexor has advanced to Phase 2 human clinical trials in patients with NASH and diabetic nephropathy.

4 January 2012 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PAPam Albaugh
Pam Albaugh
YFYi Fan
Yi Fan
YMYuan Mi
Yuan Mi
FSFangxian Sun
Fangxian Sun
FAFrancisco Adrian
Francisco Adrian
VMValentina Molteni
Valentina Molteni

20 February 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YLYahu A. Liu
Yahu A. Liu
QJQihui Jin
Qihui Jin
YZYefen Zou
Yefen Zou
QDQiang Ding
Qiang Ding
SYShanshan Yan
Shanshan Yan
JLJon Loren
Jon Loren

19 March 2015 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
HCHa-Soon Choi
Ha-Soon Choi
PRPaul V. Rucker
Paul V. Rucker
ZWZhicheng Wang
Zhicheng Wang
YFYi Fan
Yi Fan
PAPamela Albaugh
Pamela Albaugh
VMValentina Molteni
Valentina Molteni